- Home
- NGS vs SGMT Comparison
NGS vs SGMT Comparison
Compare NGS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGS
- SGMT
- Stock Information
- Founded
- NGS 1998
- SGMT 2006
- Country
- NGS United States
- SGMT United States
- Employees
- NGS N/A
- SGMT N/A
- Industry
- NGS Oilfield Services/Equipment
- SGMT
- Sector
- NGS Energy
- SGMT
- Exchange
- NGS Nasdaq
- SGMT Nasdaq
- Market Cap
- NGS 312.1M
- SGMT 269.2M
- IPO Year
- NGS 2002
- SGMT 2023
- Fundamental
- Price
- NGS $24.48
- SGMT $9.64
- Analyst Decision
- NGS Strong Buy
- SGMT Strong Buy
- Analyst Count
- NGS 2
- SGMT 5
- Target Price
- NGS $32.50
- SGMT $26.60
- AVG Volume (30 Days)
- NGS 75.2K
- SGMT 2.0M
- Earning Date
- NGS 08-13-2025
- SGMT 08-13-2025
- Dividend Yield
- NGS N/A
- SGMT N/A
- EPS Growth
- NGS 76.16
- SGMT N/A
- EPS
- NGS 1.34
- SGMT N/A
- Revenue
- NGS $161,218,000.00
- SGMT N/A
- Revenue This Year
- NGS $13.56
- SGMT N/A
- Revenue Next Year
- NGS $15.42
- SGMT N/A
- P/E Ratio
- NGS $18.12
- SGMT N/A
- Revenue Growth
- NGS 22.64
- SGMT N/A
- 52 Week Low
- NGS $16.70
- SGMT $1.73
- 52 Week High
- NGS $29.74
- SGMT $10.43
- Technical
- Relative Strength Index (RSI)
- NGS 44.42
- SGMT 68.58
- Support Level
- NGS $24.41
- SGMT $7.80
- Resistance Level
- NGS $25.46
- SGMT $9.89
- Average True Range (ATR)
- NGS 1.02
- SGMT 0.95
- MACD
- NGS -0.32
- SGMT -0.01
- Stochastic Oscillator
- NGS 8.09
- SGMT 76.43
About NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.